Enable JavaScript to visit this website.
Skip directly to content


  • EUCRISA™ is a new, steroid-free, topical ointment for mild to moderate atopic dermatitis (eczema)[1]
  • First prescription treatment indicated for mild to moderate AD to be approved in more than 10 years[2]

November 7, 2018 – KIRKLAND, QC – Pfizer Canada has announced that Health Canada has approved EUCRISA (crisaborole), and that it is now available in Canada. EUCRISA (crisaborole) ointment 2% is a new steroid-free topical phosphodieterase-4 (PDE-4) inhibitor for the treatment of mild to moderate atopic dermatitis (AD) in patients two years of age and older.1

Atopic dermatitis, often called eczema, is a chronic skin condition characterized by inflammation of the skin and skin barrier defect that is often accompanied by intense itching.[3],[4] While some patients experience periods of remission, others never experience complete remission and it becomes a lifelong condition to manage.[5] AD is estimated to affect 11% of children and 7% of adults4 and approximately 90% of people living with AD have the mild to moderate form of the condition.[6]

“Atopic dermatitis is often thought of as a childhood condition. However, many continue to suffer with it into adolescence and adulthood,” says Dr. Sam Hanna, dermatologist and medical director of Dermatology on Bloor in Toronto. “Without the proper treatment, the itching and pain of eczema can become chronic and negatively impact quality of life. The approval of EUCRISA provides an important new treatment option for the care of children and adults with mild to moderate atopic dermatitis.”

“Eczema is a debilitating disease that goes well beyond dry, itchy skin – it places a considerable burden on sufferers and their families," says Amanda Cresswell-Melville, Executive Director of the Eczema Society of Canada. “This disease can be very challenging to manage, and these challenges are multi-faceted. Having treatment options play such a valuable role in the management of this disease.”

“Pfizer Canada understands the significant challenges associated with treating atopic dermatitis,” says Vratislav Hadrava, Chief Medical Officer, Pfizer Canada. “We are proud to make EUCRISA available to Canadians, the first new prescription topical treatment to be approved in mild to moderate AD in more than 10 years.” 

About EUCRISA (crisaborole) ointment, 2%
EUCRISA is a prescription ointment used on the skin (topical) to treat mild to moderate atopic dermatitis (often called atopic eczema, or just eczema) in adults and children two years of age and older.1

About Pfizer Canada
Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best-known and most prescribed medicines and vaccines. Historically, Pfizer Inc. has invested more than US $7 billion toward developing safe and effective medicines. At Pfizer, we’re working together for a healthier world. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/PfizerCanada).


For further information:

Corporate Affairs
Pfizer Canada
1-866-9PFIZER (973-4937)


[1] EUCRISATM Product Monograph. June 7, 2018.

[2] Boguniewicz, M, Fonacier, L, Guttman-Yassky, E et al, Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120:10–22 (e2).

[3] Hanifin JM, Reed ML. A population-based survey of eczema in the United States. Dermatitis. 2007;18(2):82-91.

[4] Bieber T. Atopic dermatitis. Dermatol. 2012;1(3):203-217.

[5] Eczema Society of Canada (2017) Atopic Dermatitis:Patient Insights Report Available at: https://eczemahelp.ca/wp-content/uploads/2017/11/ESC-AD-Patient-Insights...

[6] Arkwright PD, Motala C, Subramanian H, et al. Management of difficult-to-treat atopic dermatitis. Journal of Allergy Clin Immunol Pract. 2013;1:142-151.